VR (virtual reality) equipment and platform developer Dlodlo hosted a press conference on August 8 at the New York Marriott Marquis, launching its first consumer VR product Glass V1.
The first wearable VR headset in the world to feature a real glass form design, Glass V1 can link with PC devices or the integrated terminal on Dlodlo’s self-developed external interface, D1. This solution breaks down the technology barrier of VR equipment’s high requirement for PC hardware and takes an important step in introducing VR equipment to the public.
To view the multimedia release go to:
http://www.multivu.com/players/English/7895951-dlodlo-vr-glass-launch/
The first comprehensive long-term study comparing different medications for type 2 diabetes is launching nationwide. The GRADE (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness) Study will compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treating type 2 diabetes.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64578-grade-glycemia-reduction-approaches-in-diabetes-comparative-effectiveness
The nation’s rate of preterm birth—the largest contributor to infant death in the United States -- increased again in 2016, after nearly a decade of decline, earning the nation a “C” grade on the latest March of Dimes Premature Birth Report Card.
The rate of preterm birth rose in states across the country for a second year in a row. More than 380,000 babies are born preterm in the U.S. each year, facing a greater likelihood of death before their first birthday, lifelong disabilities or chronic health conditions. An additional 8,000 babies were born prematurely in 2016 due to the increase in the preterm birth rate between 2015 and 2016, the March of Dimes says.
To view the multimedia release go to:
https://www.multivu.com/players/English/8189251-march-of-dimes-premature-birth-report-card-2017/
Studies show that more than two-thirds of aesthetically-oriented consumers are bothered by submental fullness, or “double chin.” And with social media profile images becoming more important than ever, there is interest in looking one’s best.
Submental fullness due to fat beneath the chin can impact a broad range of both men and women and because the condition can be genetic and resistant to diet and exercise. But there’s KYBELLA®, the first and only FDA-approved injectable treatment that is available by prescription only, that has been proven to improve the appearance of moderate to severe fat beneath the chin by physically destroying fat cells in the treatment area. In two pivotal clinical studies for KYBELLA®, reductions in submental fat volume were observed more frequently in the KYBELLA® treated group of 514 patients compared to the placebo group (508 patients) as measured by both clinician and patient ratings. In addition, visual and emotional impacts of submental fat (happy, bothered, self-conscious, embarrassed, looking older or overweight) were evaluated using a 6-question survey and 79% of 1 and 2-grade composite responders reported satisfaction after 12 weeks post final treatment compared with 33.6% of patients who received placebo.
To view the multimedia release go to:
http://www.multivu.com/players/English/7962051-kybella-injectable-double-chin-treatment-campaign/
Enrollment is open for online summer school at International Connections Academy (iNaCA), the accredited virtual private school serving students in grades K-12 in the United States and across the globe. Families are invited to attend an information session to learn more about the benefits of the program.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7310552-international-connections-academy-summer/
